The FDA has granted special permission for two, five year old twins girls, to receive intravenous infusions of 2-Hydroxypropyl-beta-Cyclodextrin (also known as HPBCD). The girls received the go ahead for the treatment after a "compassionate use" exception was granted. The girls are suffering from Niemann Pick Type C disease, a fatal cholesterol metabolism disorder that is often referred to as the "Childhood Alzheimer’s".
This is a gut wrenching story. If you would like to learn more, or meet Addi and Cassi Hempel, go here.
Subscribe to The Alzheimer's Reading Room--via Email
 Bob DeMarco is a citizen journalist, blogger, and Caregiver. In addition to being an experienced writer he taught at the University of Georgia , was an Associate Director and Limited Partner at Bear Stearns, the CEO of IP Group, and a mentor. Bob currently resides in Delray Beach, FL where he cares for his mother, Dorothy, who suffers from Alzheimer's disease. He has written more than 500 articles with more than 11,000 links to his work on the Internet. His content has been syndicated on Reuters, the Wall Street Journal, Fox News, Pluck, Blog Critics, and a growing list of newspaper websites. Bob is actively seeking syndication and writing assignments. |
